Alzheimer's disease is associated with the increased production and accumulation of amyloid-13 peptides in the brain. An inflammatory component has also been recognized, although the exact contribution of innate immune signalling to disease pathogenesis is still unclear. Here, vom Berg, Prokop and colleagues identify interleukin-12 (IL-12) and IL-23 signalling as a therapeutic target in this neurodegenerative disorder.
展开▼